ANG003

**ANG003** is an investigational, orally administered, non-porcine recombinant microbial pancreatic enzyme replacement therapy developed for **exocrine pancreatic insufficiency associated with cystic fibrosis**. The product combines lipase, protease, and amylase activities to replace deficient digestive enzymes and promote digestion and absorption of dietary fat, protein, and carbohydrate. ANG003 completed a Phase 1 dose-ranging study in adults with cystic fibrosis-related exocrine pancreatic insufficiency and is being evaluated in an international Phase 2 active-controlled study versus standard pancreatic enzyme replacement therapy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40750484/))

Other names

ANG-003ANG003ANG 003Amylase/Lipase/Protease replacements - Anagram Therapeutics